Collagen
This article was originally published in The Gray Sheet
Executive Summary
Fifth Circuit U.S. Court of Appeals rules that FDA approval of Collagen's Zyderm and Zyplast preempts claims alleging defective design, inadequate warnings and negligent failure to warn. The Feb. 19 decision follows a similar ruling in January by the First Circuit Court of Appeals ("The Gray Sheet" Jan. 25, p. 7).